Trials / Completed
CompletedNCT02756247
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if the combination of buparlisib and ibrutinib will lead to better treatment results in patients with relapsed or refractory Follicular lymphoma, (FL) Mantle cell lymphoma (MCL) or Diffuse Large B-cell lymphoma (DLBCL). The investigators are using buparlisib and ibrutinib because both drugs seem to block different proteins that allow cancer cells to keep growing. Blocking these proteins may help by making the cancer cells undergo cell death, which will stop uncontrolled tumor growth.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buparlisib | |
| DRUG | Ibrutinib |
Timeline
- Start date
- 2016-05-09
- Primary completion
- 2022-10-06
- Completion
- 2022-10-06
- First posted
- 2016-04-29
- Last updated
- 2022-10-10
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02756247. Inclusion in this directory is not an endorsement.